Research Analysts Issue Forecasts for RNAC Q2 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Research analysts at Wedbush issued their Q2 2025 earnings per share (EPS) estimates for shares of Cartesian Therapeutics in a report issued on Wednesday, July 9th. Wedbush analyst M. Fan expects that the company will earn ($0.74) per share for the quarter. Wedbush currently has a "Outperform" rating and a $38.00 target price on the stock. The consensus estimate for Cartesian Therapeutics' current full-year earnings is $4.56 per share. Wedbush also issued estimates for Cartesian Therapeutics' Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.65) EPS, Q1 2026 earnings at ($0.54) EPS, Q2 2026 earnings at ($0.55) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($2.18) EPS, FY2028 earnings at ($2.64) EPS and FY2029 earnings at ($2.91) EPS.

A number of other equities research analysts have also issued reports on RNAC. HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Cartesian Therapeutics in a research note on Wednesday, April 9th. Needham & Company LLC cut their price target on Cartesian Therapeutics from $41.00 to $40.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $40.00.

Cartesian Therapeutics Trading Down 1.6%

RNAC stock traded down $0.22 during trading on Friday, reaching $13.32. The company's stock had a trading volume of 54,112 shares, compared to its average volume of 99,355. Cartesian Therapeutics has a 1 year low of $8.46 and a 1 year high of $26.50. The company's fifty day moving average is $10.44 and its 200-day moving average is $14.23.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.07). The business had revenue of $1.10 million during the quarter, compared to analyst estimates of $0.69 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. MPM Bioimpact LLC boosted its holdings in shares of Cartesian Therapeutics by 9.7% during the 1st quarter. MPM Bioimpact LLC now owns 790,779 shares of the company's stock valued at $10,422,000 after purchasing an additional 69,640 shares during the last quarter. Erste Asset Management GmbH boosted its holdings in shares of Cartesian Therapeutics by 49.8% during the 1st quarter. Erste Asset Management GmbH now owns 260,011 shares of the company's stock valued at $3,432,000 after purchasing an additional 86,445 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Cartesian Therapeutics by 63.0% during the 4th quarter. Geode Capital Management LLC now owns 221,257 shares of the company's stock valued at $3,963,000 after purchasing an additional 85,557 shares during the last quarter. 683 Capital Management LLC boosted its holdings in shares of Cartesian Therapeutics by 20.0% during the 1st quarter. 683 Capital Management LLC now owns 150,000 shares of the company's stock valued at $1,977,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Cartesian Therapeutics by 50.6% during the 4th quarter. Northern Trust Corp now owns 95,030 shares of the company's stock valued at $1,702,000 after purchasing an additional 31,915 shares during the last quarter. Institutional investors own 86.95% of the company's stock.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.